Cargando…
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 2...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738091/ https://www.ncbi.nlm.nih.gov/pubmed/31383985 http://dx.doi.org/10.1038/s41416-019-0543-1 |
_version_ | 1783450781730471936 |
---|---|
author | Shi, Tingyan Jiang, Rong Pu, Hong Yang, Huijuan Tu, Dongsheng Dai, Zhiyuan Cai, Yunlang Zhang, Yuqin Cheng, Xi Jia, Huixun Tu, Ruiqin Wang, Huaying Tang, Jie Luan, Yuting Cai, Shumo Zang, Rongyu |
author_facet | Shi, Tingyan Jiang, Rong Pu, Hong Yang, Huijuan Tu, Dongsheng Dai, Zhiyuan Cai, Yunlang Zhang, Yuqin Cheng, Xi Jia, Huixun Tu, Ruiqin Wang, Huaying Tang, Jie Luan, Yuting Cai, Shumo Zang, Rongyu |
author_sort | Shi, Tingyan |
collection | PubMed |
description | Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC–IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49–1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47–0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer. Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012). |
format | Online Article Text |
id | pubmed-6738091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67380912020-08-06 Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study Shi, Tingyan Jiang, Rong Pu, Hong Yang, Huijuan Tu, Dongsheng Dai, Zhiyuan Cai, Yunlang Zhang, Yuqin Cheng, Xi Jia, Huixun Tu, Ruiqin Wang, Huaying Tang, Jie Luan, Yuting Cai, Shumo Zang, Rongyu Br J Cancer Brief Communication Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC–IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49–1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47–0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer. Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012). Nature Publishing Group UK 2019-08-06 2019-08-27 /pmc/articles/PMC6738091/ /pubmed/31383985 http://dx.doi.org/10.1038/s41416-019-0543-1 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Brief Communication Shi, Tingyan Jiang, Rong Pu, Hong Yang, Huijuan Tu, Dongsheng Dai, Zhiyuan Cai, Yunlang Zhang, Yuqin Cheng, Xi Jia, Huixun Tu, Ruiqin Wang, Huaying Tang, Jie Luan, Yuting Cai, Shumo Zang, Rongyu Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title_full | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title_fullStr | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title_full_unstemmed | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title_short | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
title_sort | survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738091/ https://www.ncbi.nlm.nih.gov/pubmed/31383985 http://dx.doi.org/10.1038/s41416-019-0543-1 |
work_keys_str_mv | AT shitingyan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT jiangrong survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT puhong survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT yanghuijuan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT tudongsheng survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT daizhiyuan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT caiyunlang survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT zhangyuqin survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT chengxi survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT jiahuixun survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT turuiqin survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT wanghuaying survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT tangjie survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT luanyuting survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT caishumo survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT zangrongyu survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy AT survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy |